ACHL Stock Overview
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.83|
|52 Week High||US$18.95|
|52 Week Low||US$3.55|
|1 Month Change||-27.74%|
|3 Month Change||-38.72%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-76.86%|
Recent News & Updates
Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|ACHL||US Biotechs||US Market|
Return vs Industry: Insufficient data to determine how ACHL performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ACHL performed against the US Market.
|ACHL Average Weekly Movement||10.3%|
|Biotechs Industry Average Movement||10.4%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||15.4%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: ACHL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ACHL's weekly volatility (10%) has been stable over the past year.
About the Company
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company’s lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer.
Achilles Therapeutics Fundamentals Summary
|ACHL fundamental statistics|
Is ACHL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ACHL income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.37|
|Net Profit Margin||0.00%|
How did ACHL perform over the long term?See historical performance and comparison
Is Achilles Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ACHL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ACHL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ACHL is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ACHL is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ACHL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ACHL is good value based on its PB Ratio (0.5x) compared to the US Biotechs industry average (2x).
How is Achilles Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ACHL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ACHL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ACHL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ACHL is forecast to have no revenue next year.
High Growth Revenue: ACHL is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ACHL is forecast to be unprofitable in 3 years.
How has Achilles Therapeutics performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: ACHL is currently unprofitable.
Growing Profit Margin: ACHL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ACHL's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ACHL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACHL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: ACHL has a negative Return on Equity (-18.28%), as it is currently unprofitable.
How is Achilles Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ACHL's short term assets ($298.3M) exceed its short term liabilities ($15.4M).
Long Term Liabilities: ACHL's short term assets ($298.3M) exceed its long term liabilities ($9.5M).
Debt to Equity History and Analysis
Debt Level: ACHL is debt free.
Reducing Debt: ACHL had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ACHL has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ACHL has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 71.4% each year.
What is Achilles Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ACHL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ACHL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ACHL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ACHL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ACHL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Iraj Ali (45 yo)
Dr. Iraj Ali, Ph.D. serves as Chief Executive Officer at Achilles Therapeutics Plc since December 10, 2018 and served as its Interim Chief Executive Officer since January 2018 until December 10, 2018. Dr....
Experienced Management: ACHL's management team is seasoned and experienced (5 years average tenure).
Experienced Board: ACHL's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: ACHL only recently listed within the past 12 months.
Achilles Therapeutics plc's employee growth, exchange listings and data sources
- Name: Achilles Therapeutics plc
- Ticker: ACHL
- Exchange: NasdaqGS
- Founded: 2016
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$155.511m
- Shares outstanding: 40.60m
- Website: https://www.achillestx.com
Number of Employees
- Achilles Therapeutics plc
- 245 Hammersmith Road
- Greater London
- W6 8PW
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/27 00:12|
|End of Day Share Price||2022/01/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.